Noncontiguous Local Recurrence of Posterior Uveal Melanoma After Cobalt 60 Episcleral Plaque Therapy

Noncontiguous Tumor Recurrence of Posterior Uveal Melanoma After Transscleral Local Resection

“…10,11,[35][36][37] In our series, 3 of 9 patients with NTR developed systemic metastatic disease. Duker and colleagues 9 reported that 3 of their 4 patients died of metastatic disease within 7 months after the diagnosis of their NTR. However, the average basal diameter of the distant tumor recurrences in their study was 13.75 mm, 9 whereas the average diameter of the recurrent lesions in our study was only 5.8 mm.…”

“…Duker and colleagues 9 reported that 3 of their 4 patients died of metastatic disease within 7 months after the diagnosis of their NTR. However, the average basal diameter of the distant tumor recurrences in their study was 13.75 mm, 9 whereas the average diameter of the recurrent lesions in our study was only 5.8 mm. Because of these confounding variables and the small number of patients in both series, there is insufficient evidence to make conclusions regarding the relationship between NTR and systemic prognosis.…”

Noncontiguous Tumor Recurrence of Posterior Uveal Melanoma After Transscleral Local Resection

“…10,11,[35][36][37] In our series, 3 of 9 patients with NTR developed systemic metastatic disease. Duker and colleagues 9 reported that 3 of their 4 patients died of metastatic disease within 7 months after the diagnosis of their NTR. However, the average basal diameter of the distant tumor recurrences in their study was 13.75 mm, 9 whereas the average diameter of the recurrent lesions in our study was only 5.8 mm.…”

“…Duker and colleagues 9 reported that 3 of their 4 patients died of metastatic disease within 7 months after the diagnosis of their NTR. However, the average basal diameter of the distant tumor recurrences in their study was 13.75 mm, 9 whereas the average diameter of the recurrent lesions in our study was only 5.8 mm. Because of these confounding variables and the small number of patients in both series, there is insufficient evidence to make conclusions regarding the relationship between NTR and systemic prognosis.…”

Non‐contiguous recurrence or secondary choroidal melanoma following plaque radiotherapy

“…Most irradiated melanomas undergo tumour regression 4 . The risk of non‐continuous recurrence is less than 1%, which usually occurs within 1–2 years after plaque placement 3 . Several mechanisms have been postulated to explain the non‐contiguous recurrence: the tumour cells released into subretinal fluid, haematogenous spread, secondary radiation‐induced malignances and susceptibility to uveal melanoma formation 5 .…”

“…It is known that most of choroidal melanomas with subretinal fluid do not develop recurrences away from the original tumour. Additionally, non‐contiguous recurrence can be seen in eyes with tumours that were not associated with vitreous haemorrhages or extension through the retina 3–7 . So, the correct mechanism for this recurrence or secondary tumour remains unclear.…”

“…In these cases the recurrences occurred within 1–2 years after plaque treatment and the primary tumour had not fully regressed at the time of recurrences. Additionally, three of these patients died owing to metastases varying between 3 and 6 months after diagnosis of the secondary tumour 3 . Our patient had no clinical or laboratory evidences of metastases (3 years of follow up only) and his non‐contiguous tumour recurred years after total regression of the primary tumour.…”

Noncontiguous Tumor Recurrence of Posterior Uveal Melanoma After Transscleral Local Resection

“…10,11,[35][36][37] In our series, 3 of 9 patients with NTR developed systemic metastatic disease. Duker and colleagues 9 reported that 3 of their 4 patients died of metastatic disease within 7 months after the diagnosis of their NTR. However, the average basal diameter of the distant tumor recurrences in their study was 13.75 mm, 9 whereas the average diameter of the recurrent lesions in our study was only 5.8 mm.…”

“…Duker and colleagues 9 reported that 3 of their 4 patients died of metastatic disease within 7 months after the diagnosis of their NTR. However, the average basal diameter of the distant tumor recurrences in their study was 13.75 mm, 9 whereas the average diameter of the recurrent lesions in our study was only 5.8 mm. Because of these confounding variables and the small number of patients in both series, there is insufficient evidence to make conclusions regarding the relationship between NTR and systemic prognosis.…”

Non‐contiguous recurrence or secondary choroidal melanoma following plaque radiotherapy

“…Most irradiated melanomas undergo tumour regression 4 . The risk of non‐continuous recurrence is less than 1%, which usually occurs within 1–2 years after plaque placement 3 . Several mechanisms have been postulated to explain the non‐contiguous recurrence: the tumour cells released into subretinal fluid, haematogenous spread, secondary radiation‐induced malignances and susceptibility to uveal melanoma formation 5 .…”

“…It is known that most of choroidal melanomas with subretinal fluid do not develop recurrences away from the original tumour. Additionally, non‐contiguous recurrence can be seen in eyes with tumours that were not associated with vitreous haemorrhages or extension through the retina 3–7 . So, the correct mechanism for this recurrence or secondary tumour remains unclear.…”

“…In these cases the recurrences occurred within 1–2 years after plaque treatment and the primary tumour had not fully regressed at the time of recurrences. Additionally, three of these patients died owing to metastases varying between 3 and 6 months after diagnosis of the secondary tumour 3 . Our patient had no clinical or laboratory evidences of metastases (3 years of follow up only) and his non‐contiguous tumour recurred years after total regression of the primary tumour.…”

Noncontiguous Tumor Recurrence of Posterior Uveal Melanoma After Transscleral Local Resection

“…10,11,[35][36][37] In our series, 3 of 9 patients with NTR developed systemic metastatic disease. Duker and colleagues 9 reported that 3 of their 4 patients died of metastatic disease within 7 months after the diagnosis of their NTR. However, the average basal diameter of the distant tumor recurrences in their study was 13.75 mm, 9 whereas the average diameter of the recurrent lesions in our study was only 5.8 mm.…”

“…Duker and colleagues 9 reported that 3 of their 4 patients died of metastatic disease within 7 months after the diagnosis of their NTR. However, the average basal diameter of the distant tumor recurrences in their study was 13.75 mm, 9 whereas the average diameter of the recurrent lesions in our study was only 5.8 mm. Because of these confounding variables and the small number of patients in both series, there is insufficient evidence to make conclusions regarding the relationship between NTR and systemic prognosis.…”

Non‐contiguous recurrence or secondary choroidal melanoma following plaque radiotherapy

“…Most irradiated melanomas undergo tumour regression 4 . The risk of non‐continuous recurrence is less than 1%, which usually occurs within 1–2 years after plaque placement 3 . Several mechanisms have been postulated to explain the non‐contiguous recurrence: the tumour cells released into subretinal fluid, haematogenous spread, secondary radiation‐induced malignances and susceptibility to uveal melanoma formation 5 .…”

“…It is known that most of choroidal melanomas with subretinal fluid do not develop recurrences away from the original tumour. Additionally, non‐contiguous recurrence can be seen in eyes with tumours that were not associated with vitreous haemorrhages or extension through the retina 3–7 . So, the correct mechanism for this recurrence or secondary tumour remains unclear.…”

“…In these cases the recurrences occurred within 1–2 years after plaque treatment and the primary tumour had not fully regressed at the time of recurrences. Additionally, three of these patients died owing to metastases varying between 3 and 6 months after diagnosis of the secondary tumour 3 . Our patient had no clinical or laboratory evidences of metastases (3 years of follow up only) and his non‐contiguous tumour recurred years after total regression of the primary tumour.…”